Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Stratigos, A. J.
Sekulic, A.
Peris, K.
Bechter, O.
Dutriaux, C.
Kaatz, M.
Lewis, K. D.
Basset-Seguin, N.
Chang, A. L. S.
Dalle, S.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
